Skip to main content
. 2025 Apr 11;25(1):79–88. doi: 10.1007/s40268-025-00506-9

Table 1.

Baseline patient data

Projects/indicators Value mean (Q25, Q75)
A (n = 180) B (n = 150) C (n = 120) D (n = 95)
Male/female 101/79 82/68 62/58 52/43
Age (years) 4.59 (1, 8) 4.93 (1, 9) 4.94 (1, 8) 5.4 (2, 8)
Weight (kg) 21.97 (9.54, 28.75) 22.3 (10, 29.25) 22.25 (10.5, 28) 23.08 (12.5, 29)
Surface area (m2) 0.78 (0.43, 1.08) 0.8 (0.45, 1.08) 0.8 (0.46, 1.08) 0.83 (0.54, 1.08)
WBC (109/L) 7.97 (5.8, 9.49) 8.11 (6.15, 9.46) 7.91 (5.91, 9.3) 7.77 (5.83, 9.68)
RBC (1012/L) 4.74 (4.41, 5.11) 4.82 (4.56, 5.12) 4.94 (4.64, 5.18) 4.93 (4.69, 5.22)
PLT (109/L) 304.07 (227, 371.5) 317.15 (236.75, 381.5) 328.66 (262, 408) 320.05 (263, 377)
HGB (g/L) 122.8 (113.25, 131) 124.21 (118.5, 132) 123.9 (120, 130) 122.8(117, 132)
AST (U/L) 37.71 (26.3, 43.3) 36.08 (26.3, 42.3) 37.44 (28.1, 43.83) 36.15 (25.8, 40.4)
ALT (U/L) 25.71 (12.2, 26.68) 22.77 (11.88, 24.33) 22.57 (13.03, 24.28) 26.41 (11.3, 22.6)
TBIL (μmol/L) 9.03 (6.1, 10.51) 8.1 (5.93, 10.25) 8.01 (6.03, 9.54) 8.17 (6.1, 9.35)
ALB (g/L) 42.31 (40.1, 44.68) 42.57 (41.08, 44.73) 42.86 (41.2, 44.3) 42.28 (41, 43.9)
CREA (μmol/L) 26.87 (20.5, 32.3) 27.76 (20.4, 33.83) 28.81 (21.73, 34.35) 29.6 (22.5, 34.1)
C0 (ng/mL) 7.68 (4.51, 9.92) 8.12 (4.73, 10.29) 7.42 (5.02, 9.06) 6.61 (4.41, 7.89)
D (mg/day) 1.06 (0.5, 1.5) 1.14 (0.67, 1.5) 1.13 (0.61, 1.5) 1.18 (0.75, 1.5)
C0/D (ng/mL)/(mg/day) 11.56 (3.55, 11.86) 10.53 (3.8, 11.89) 9.68 (3.49, 12.47) 7.84 (2.57, 9.88)

Group A, B, C, and D: 1 week after sirolimus (group A), 2 weeks after sirolimus (group B), 4 weeks after sirolimus (group C), and 12 weeks after sirolimus (group D). A (n = 180), the volume of patients in group A was 180

Q25 the 25th percentile, Q75 the 75th percentile, WBC leukocyte count, RBC erythrocyte count, PLT platelet count, HGB hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, TBIL total bilirubin, ALB albumin, CREA creatinine, C0 sirolimus trough concentration, D dose